From the Mayo Clinic, Jacksonville, Fla.
An otherwise healthy 46-year-old man presented with a 1-year history of an ill-defined acral eruption that had evolved over several weeks into reddish-brown papules and nodules, together with a progressive inflammatory polyarthritis. Skin lesions ranging from several millimeters to several centimeters in diameter were present on the dorsal and palmar aspects of the hands (Figure 1) and on the forearms, extensor elbows, chest, paranasal face, neck, pinnae, and scalp. A skin biopsy revealed an intradermal infiltrate composed predominantly of histiocytes and multinucleated giant cells. Many of the cells had abundant "ground glass" cytoplasm with fine periodic acid-Schiff–positive granules (Figure 2). There was severe stiffness, pain, and swelling associated with bilateral synovitis of the metacarpophalangeal joints, distal and proximal interphalangeal joints, wrists, elbows, shoulders, knees, ankles, and forefeet.
Hands before treatment with etanercept.
A skin biopsy specimen revealed dermal infiltrate of histiocytes and multinucleated giant cells with abundant "ground glass" cytoplasm.
Laboratory values, including complete blood cell count, general chemistry panel, erythrocyte sedimentation rate, rheumatoid factor, and antinuclear antibodies were within normal limits except for an elevated total cholesterol level of 262 mg/dL (6.80 mmol/L). The test result for perinuclear antineutrophil cytoplasmic antibodies was positive but no titer was reported and antibodies to myeloperoxidase were not obtained. A chest radiograph was unremarkable.
The patient was diagnosed with multicentric reticulohistiocytosis (MRH) and initially managed with 20 mg of methotrexate weekly and 20 to 40 mg of prednisone daily for 2 months. Hydroxychloroquine was added to this regimen for 7 months with little benefit. Subsequent treatment with chlorambucil and prednisone for 3 months was accompanied by a worsening of the skin and joint disease. Radiographs taken 2 years after disease onset revealed erosive articular damage in the hands (Figure 3) and right hip. Combination therapy with cyclophosphamide (up to 200 mg daily), methotrexate (up to 25 mg weekly), and prednisone (20 mg daily) resulted in gradual improvement of only the skin eruption over 8 months, but cyclophosphamide was discontinued after the onset of gross hematuria.
Radiograph of the left hand. Marginal erosions are present at multiple joints in the hand and wrist (most pronounced at the distal interphalangeal joint of the index finger), with relatively mild osteopenia. Similar changes were found in a radiograph of the right hand.
Multicentric reticulohistiocytosis is a potentially disfiguring and crippling disease for which no consensus has been reached regarding treatment. Therapies with corticosteroids, hydroxychloroquine, methotrexate, alkylating agents such as chlorambucil and cyclophosphamide, and azathioprine have been used with mixed success.1- 4 The challenge in this case was to determine a safe and effective treatment for both the skin and joint manifestations of the disease.
Immunohistochemical staining of the inflammatory infiltrate in MRH has demonstrated the presence of histiocytes of a monocyte-macrophage origin and an abundance of cytokines, including tumor necrosis factor α (TNF-α).5- 7 The production of TNF-α and other cytokines by monocytes and macrophages plays a central role in many inflammatory conditions: TNF-α has been found in synovium and synovial fluid from joints of patients with several forms of inflammatory arthritis8- 10 that may be successfully treated with anti-TNF agents. The predominance of histiocytes in the infiltrate of MRH and the detection of TNF-α inspired a trial of an anti-TNF agent, etanercept, as treatment for our patient.
Biweekly treatment with etanercept, 25 mg by subcutaneous injection, was started in addition to continuing treatment with prednisone, 20 mg daily, and methotrexate, 15 mg weekly. With this regimen there was improvement in skin and joint symptoms within 1 month, and prednisone was tapered over 7 months. The patient experienced a flare of skin lesions and arthritis as the dose of prednisone was reduced to 10 mg daily. At that time, treatment with etanercept, 25 mg biweekly, and prednisone, 10 mg daily, was continued, and methotrexate was replaced with leflunamide, 20 mg daily. Skin lesions and synovitis completely resolved with this regimen, which permitted a decrease of the prednisone dosage to 5 mg daily without a flare of symptoms for 10 months (Figure 4). There was some progression of articular deformities despite the control of synovitis. We believe that this resulted from articular damage that had previously occurred. The dosages of leflunamide and prednisone were recently decreased to 20 mg every other day and 4 mg daily, respectively, and treatment with etanercept was continued. The patient has remained symptom free for 2 months. We plan to continue tapering prednisone and leflunamide dosages if symptoms remain controlled.
Hands after 7 months of treatment with etanercept.
A rare multisystem disease of unknown etiology characterized by a histiocytic infiltrate in the dermis and synovium, MRH manifests as a papulonodular eruption and symmetric inflammatory polyarthritis. It tends to have an insidious onset, most commonly in the fourth decade of life, and is slightly predominant in women. At presentation, about 40% of patients have only joint symptoms, 30% only skin symptoms, and 30% both skin and joint symptoms.11 Active disease often remits after approximately 8 years12 and, although it is not considered a paraneoplastic syndrome, it occurs with an associated malignancy in about 20% of cases.11 Other sites of involvement can include the heart, lungs, thyroid, and bone marrow.11,13 Constitutional symptoms such as fever, malaise, and weight loss have been described, as have an elevated erythrocyte sedimentation rate, anemia, and hypercholesterolemia.11 Antibodies to neutrophil cytoplasmic antigens have not been reported in MRH. Antibody specificity was not determined in our patient.
Cutaneous manifestations include pink, red, or brown papules and nodules ranging from 1 millimeter to several centimeters in diameter and occurring most frequently on the dorsal aspect of the hands and on the face. Other sites of involvement include the arms, scalp, pinnae, and neck. Papules often occur in a periungual distribution, producing a characteristic "coral beads" appearance. Mucosal involvement, which includes the tongue and buccal or nasal mucosa, occurs in roughly one third of cases.11
A symmetric inflammatory polyarthritis can affect any synovial joint, including the hands, knees, wrists, shoulders, elbows, ankles, hips, feet, and spine.11 The arthritis can be rapidly progressive and destructive. Well-circumscribed marginal erosions and juxtarticular reabsorption are typical, often creating the appearance of a widening of the joint space.11,12 Severe involvement of the interphalangeal joints may cause shortening and telescoping of the involved fingers, forming characteristic "opera glass hands." It has been proposed that this joint destruction is mediated by urokinase released by activated histiocytes.14
Histologically, MRH can be recognized by a dermal or synovial infiltrate containing histiocytes and multinucleated giant cells with abundant eosinophilic, finely granular, ground-glasslike cytoplasm. The cytoplasm is periodic acid–Schiff positive and diastase resistant.13 These giant cells may be few in early lesions. In addition to histiocytes, small numbers of lymphocytes may be found in the infiltrate. As mentioned, immunohistochemical staining has revealed the presence of inflammatory cytokines, including TNF-α, interleukin 1 β, and interleukin 12.5- 7
As in MRH, high levels of TNF-α have been found in the synovium and synovial fluid of joints affected by other inflammatory arthritides such as rheumatoid arthritis, juvenile rheumatoid arthritis, and psoriatic arthritis,8- 10,15 all of which have been successfully treated with anti-TNF agents.16- 18 Mice overexpressing TNF-α also develop joint inflammation.19 Etanercept is a genetically engineered fusion protein made up of soluble TNF-α receptor fused to the Fc portion of IgG1 that binds circulating TNF-α. The predominance of histiocytes and presence of TNF-α in the inflammatory infiltrate of affected skin and joints make anti–TNF-α agents a logical therapeutic option in MRH. Matejicka et al20 recently reported a case of MRH in a 22-year-old woman resistant to treatment with prednisone, methotrexate, nonsteroidal anti-inflammatory drugs, hydroxychloroquine, cyclophosphamide, and cyclosporine who responded well to a combination of etanercept, methotrexate, and prednisone. This patient remained symptom free with a regimen of etanercept and hydroxychloroquine. Our experience with etanercept also suggests that anti-TNF agents may have an important role in the treatment of MRH.
Correspondence: Kenneth T. Calamia, MD, Mayo Clinic, 4500 San Pablo Rd, Jacksonville, FL 32224 (firstname.lastname@example.org).
Accepted for publication October 10, 2003.
The authors have no relevant financial interest in this article.
Clinicians, local and regional societies, residents, and fellows are invited to submit cases of challenges in management and therapeutics to this section. Cases should follow the established pattern. Submit 4 double-spaced copies of the manuscript with right margins nonjustified and 4 sets of the illustrations. Photomicrographs and illustrations must be clear and submitted as positive color transparencies (35-mm slides) or black-and-white prints. Do not submit color prints unless accompanied by original transparencies. Material should be accompanied by the required copyright transfer statement, as noted in "Instructions for Authors." Material for this section should be submitted to George J. Hruza, MD, Laser and Dermatologic Surgery Center Inc, 14377 Woodlake Dr, Suite 111, St Louis, MO 63017.
Thank you for submitting a comment on this article. It will be reviewed by JAMA Dermatology editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 41
Customize your page view by dragging & repositioning the boxes below.
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.